<DOC>
	<DOC>NCT00830076</DOC>
	<brief_summary>This study will assess the effects of sitagliptin and metformin alone and after co-administration on incretin hormone concentrations in patients with Type 2 diabetes.</brief_summary>
	<brief_title>A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Female subjects must have a negative pregnancy test Subject has type 2 diabetes and is not currently receiving treatment with an oral AHA agent, has not received such treatment for 3 months prior to study, and/or has not received more than 4 total weeks treatment with an oral AHA agent for 12 to 18 months prior to the study Subject is a nonsmoker or has not smoked and/or used nicotine for at least 6 months Subject has a history of stroke, seizures, or major neurological disorders Female subject is breastfeeding Subject cannot refrain from use of any prescription or nonprescription drugs beginning 2 weeks prior to first dose of study drug Subject consumes more than 3 alcoholic beverages per day Subject consumes more than 6 caffeinated beverages per day Subject has had major surgery, or has donated or lost 1 unit of blood within 4 weeks of screening Subject has a history of cancer, except certain skin or cervical cancer or other cancers treated more than 10 years prior to screening Subject has a history of multiple and/or severe allergies or intolerance to drugs or food</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>